Editas Medicine (NASDAQ: EDIT) reported Q2 EPS of ($0.82), $0.12 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $510 thousand versus the consensus estimate of $4.78 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.